Literature DB >> 23271701

The role of inflammasome-derived IL-1 in driving IL-17 responses.

Kingston H G Mills1, Lara S Dungan, Sarah A Jones, James Harris.   

Abstract

NLRs are members of the PRR family that sense microbial pathogens and mediate host innate immune responses to infection. Certain NLRs can assemble into a multiprotein complex called the inflammasome, which activates casapse-1 required for the cleavage of immature forms of IL-1β and IL-18 into active, mature cytokines. The inflammasome is activated by conserved, exogenous molecules from microbes and nonmicrobial molecules, such as asbestos, alum, or silica, as well as by endogenous danger signals, such as ATP, amyloid-β, and sodium urate crystals. Activation of the inflammasome is a critical event triggering IL-1-driven inflammation and is central to the pathology of autoinflammatory diseases, such as gout and MWS. Recent studies have also shown IL-1 or IL-18, in synergy with IL-23, can promote IL-17-prduction from Th17 cells and γδ T cells, and this process can be regulated by autophagy. IL-1-driven IL-17 production plays a critical role in host protective immunity to infection with fungi, bacteria, and certain viruses. However, Th17 cells and IL-17-seceting γδ T cells, activated by inflammasome-derived IL-1 or IL-18, have major pathogenic roles in many autoimmune diseases. Consequently, inflammasomes are now major drug targets for many autoimmune and chronic inflammatory diseases, as well as autoinflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271701     DOI: 10.1189/jlb.1012543

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  64 in total

1.  Inflammasome Activity in Non-Microbial Lung Inflammation.

Authors:  Jennifer L Ather; Rebecca A Martin; Karina Ckless; Matthew E Poynter
Journal:  J Environ Immunol Toxicol       Date:  2014-09-20

2.  IL-1 watches the watchmen.

Authors:  Alejandro V Villarino; Arian Laurence
Journal:  Nat Immunol       Date:  2015-03       Impact factor: 25.606

Review 3.  Metabolic regulation of inflammasomes in inflammation.

Authors:  Qiuli Yang; Ruichen Liu; Qing Yu; Yujing Bi; Guangwei Liu
Journal:  Immunology       Date:  2019-04-08       Impact factor: 7.397

Review 4.  Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Authors:  Tara Elizabeth Scott; Barbara K Kemp-Harper; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2018-06-27       Impact factor: 8.739

Review 5.  Molecular pathology of macrophages and interleukin-17 in age-related macular degeneration.

Authors:  Chi-Chao Chan; Daniel Ardeljan
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

6.  Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.

Authors:  Julie Dragon; Joyce Thompson; Maximilian MacPherson; Arti Shukla
Journal:  J Cell Biochem       Date:  2015-08       Impact factor: 4.429

Review 7.  Are Th17 Cells Playing a Role in Immunity to Dermatophytosis?

Authors:  Marie-Pierre Heinen; Ludivine Cambier; Laurence Fievez; Bernard Mignon
Journal:  Mycopathologia       Date:  2016-11-23       Impact factor: 2.574

8.  Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice.

Authors:  S M Krishnan; J K Dowling; Y H Ling; H Diep; C T Chan; D Ferens; M M Kett; A Pinar; C S Samuel; A Vinh; T V Arumugam; T D Hewitson; B K Kemp-Harper; A A B Robertson; M A Cooper; E Latz; A Mansell; C G Sobey; G R Drummond
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

Review 9.  Basic biology and role of interleukin-17 in immunity and inflammation.

Authors:  Camille Zenobia; George Hajishengallis
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

10.  FcγR mediates TLR2- and Syk-dependent NLRP3 inflammasome activation by inactivated Francisella tularensis LVS immune complexes.

Authors:  Ellen B Duffy; Sivakumar Periasamy; Danielle Hunt; James R Drake; Jonathan A Harton
Journal:  J Leukoc Biol       Date:  2016-06-30       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.